Pre-operative Atorvastatin Therapy to Decrease the Systemic Inflammatory Response after Coronary Artery Bypass Grafting

Basit Öğe Kaydı
dc.contributor.authorDereli, Y.
dc.contributor.authorEge, E.
dc.contributor.authorKurban, S.
dc.contributor.authorNarin, C.
dc.contributor.authorSarigul, A.
dc.contributor.authorYeniterzi, M.
dc.date.accessioned2020-03-26T17:27:29Z
dc.date.available2020-03-26T17:27:29Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description57th International Congress of the European-Society-for-Cardiovascular-Surgery -- APR 24-27, 2008 -- Barcelona, SPAINen_US
dc.description.abstractThe effect of pre-operative atorvastatin on systemic inflammatory response syndrome (SIRS), often seen after coronary artery bypass grafting (CABG) was evaluated in 40 patients undergoing elective CABG. Patients were divided into two groups: group I (pre-operative LDL cholesterol 100 mg/dl; n = 20) received 20 mg/day atorvastatin for at least 15 days pre-operatively; group II (pre-operative LDL cholesterol < 100 mg/dl; n = 20) did not receive antihyperlipidaemic agents. All patients underwent CABG with cardiopulmonary bypass. Blood samples were taken pre-operatively and 24 h post-operatively. There were no significant differences between the two groups in terms of demographic, pre-operative or operative parameters. At 24 h post-operatively, median high-sensitivity C-reactive protein and mean interleukin-6 levels were significantly lower in group I compared with group II. There were no other significant differences in postoperative parameters between the two groups, except for duration of stay in the intensive care unit, which was shorter in group I patients. In conclusion, pre-operative atorvastatin treatment in patients undergoing elective CABG decreased inflammation parameters and could be effective in preventing SIRS.en_US
dc.description.sponsorshipEuropean Soc Cardiovasc Surgen_US
dc.identifier.doi10.1177/147323000803600611en_US
dc.identifier.endpage1254en_US
dc.identifier.issn0300-0605en_US
dc.identifier.issn1473-2300en_US
dc.identifier.issue6en_US
dc.identifier.pmid19094433en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1248en_US
dc.identifier.urihttps://dx.doi.org/10.1177/147323000803600611
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22577
dc.identifier.volume36en_US
dc.identifier.wosWOS:000262024700011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSAGE PUBLICATIONS LTDen_US
dc.relation.ispartofJOURNAL OF INTERNATIONAL MEDICAL RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectCARDIOPULMONARY BYPASSen_US
dc.subjectCORONARY ARTERY BYPASS GRAFTINGen_US
dc.subjectATORVASTATINen_US
dc.subjectSTATINSen_US
dc.subjectSYSTEMIC INFLAMMATORY RESPONSE SYNDROMEen_US
dc.titlePre-operative Atorvastatin Therapy to Decrease the Systemic Inflammatory Response after Coronary Artery Bypass Graftingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu